Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Folate as a potential treatment for lethal ventricular arrhythmias in TANGO2-deficiency disorder
Weiyi Xu, Yingqiong Cao, Sara B. Stephens, Maria Jose Arredondo, Yifan Chen, William Perez, Liang Sun, Andy C. Yu, Jean J. Kim, Seema R. Lalani, Na Li, Frank T. Horrigan, Francisco Altamirano, Xander H.T. Wehrens, Christina Y. Miyake, Lilei Zhang
Weiyi Xu, Yingqiong Cao, Sara B. Stephens, Maria Jose Arredondo, Yifan Chen, William Perez, Liang Sun, Andy C. Yu, Jean J. Kim, Seema R. Lalani, Na Li, Frank T. Horrigan, Francisco Altamirano, Xander H.T. Wehrens, Christina Y. Miyake, Lilei Zhang
View: Text | PDF
Research Article Cardiology Genetics

Folate as a potential treatment for lethal ventricular arrhythmias in TANGO2-deficiency disorder

  • Text
  • PDF
Abstract

TANGO2-deficiency disorder (TDD) is an autosomal-recessive genetic disease caused by biallelic loss-of-function variants in the TANGO2 gene. TDD-associated cardiac arrhythmias are recalcitrant to standard antiarrhythmic medications and constitute the leading cause of death. Disease modeling for TDD has been primarily carried out using human dermal fibroblast and, more recently, in Drosophila by multiple research groups. No human cardiomyocyte system has been reported, which greatly hinders the investigation and understanding of TDD-associated arrhythmias. Here, we established potentially novel patient-derived induced pluripotent stem cell differentiated cardiomyocyte (iPSC-CM) models that recapitulate key electrophysiological abnormalities in TDD. These electrophysiological abnormalities were rescued in iPSC-CMs with either adenoviral expression of WT-TANGO2 or correction of the pathogenic variant using CRISPR editing. Our natural history study in patients with TDD suggests that the intake of multivitamin/B complex greatly diminished the risk of cardiac crises in patients with TDD. In agreement with the clinical findings, we demonstrated that high-dose folate (vitamin B9) virtually abolishes arrhythmias in TDD iPSC-CMs and that folate’s effect was blocked by the dihydrofolate reductase inhibitor methotrexate, supporting the need for intracellular folate to mediate antiarrhythmic effects. In summary, data from TDD iPSC-CM models together with clinical observations support the use of B vitamins to mitigate cardiac crises in patients with TDD, providing potentially life-saving treatment strategies during life-threatening events.

Authors

Weiyi Xu, Yingqiong Cao, Sara B. Stephens, Maria Jose Arredondo, Yifan Chen, William Perez, Liang Sun, Andy C. Yu, Jean J. Kim, Seema R. Lalani, Na Li, Frank T. Horrigan, Francisco Altamirano, Xander H.T. Wehrens, Christina Y. Miyake, Lilei Zhang

×

Figure 2

Generation of patient-derived iPSC-CMs and isogenic controls from TAN016 and TAN002.

Options: View larger image (or click on image) Download as PowerPoint
Generation of patient-derived iPSC-CMs and isogenic controls from TAN016...
(A) G154R and ΔE3–9 variants in human TANGO2 locus. Coding regions in exons are shown in black. (B) RT-PCR for TAN016 using primer pairs targeting exon 1–2 (E1–2) or exon 7–8 (E7–8) of WT-TANGO2 transcript. Sample from an unrelated WT line was used as positive control. (C) Transcriptional level of TANGO2 in the control, TAN016+Ad-GFP (Ad-GFP), and TAN016+Ad-WT (Ad-WT) iPSC-CMs. Quantification was performed by RT-PCR and normalized to the level of the control iPSC-CMs (n = 3). PPIB was used as internal control. Data are mean ± SEM. (D) Immunoblotting showing the adenoviral expression of WT-TANGO2 protein in TAN016 iPSC-CMs. A 3XFLAG tag was added to the C-terminus of the ectopic TANGO2 protein. Image on the right demonstrates the specificity of TANGO2 polyclonal antibody using an anti-FLAG antibody. Na+/K+ ATPase (NKA) was used as loading control. (E) Sanger sequencing confirmed the genotypes in TAN002 and its isogenic correction line TAN002c. (F) Immunoblotting showing the TANGO2 protein level in TAN002, TAN002c, and control iPSC-CMs detected by the TANGO2 polyclonal antibody. β-Tubulin was used as loading control. (G) Transcriptional level of key cardiac marker genes in 4 iPSC and 5 iPSC-CM lines used in the study. Quantification was performed by RT-PCR and normalized to control iPSC group (n = 3–6). PPIB was used as internal control. Mean value for each line is presented in the heatmap. (H) Immunofluorescence staining of α-actinin (top) and cardiac troponin T (cTnT; bottom) in TAN016+Ad-GFP/WT-TANGO2, TAN002, and TAN002c. Nuclei were stained by DAPI in blue. Scale bar: 30 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts